New cancer pill shows promise in early trial
NCT ID NCT04991480
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tested a new oral drug called ART4215 in 93 people with advanced or metastatic solid tumors, including breast cancer. The main goals were to find a safe dose and check for side effects when given alone or with other cancer drugs (talazoparib or niraparib). Researchers also looked at whether the drug could slow tumor growth.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ART4215 (a DNA repair blocker, taken as a pill)
What this could lead to
If successful, this could lead to a new treatment option for people with advanced solid tumors, especially those with breast cancer.
What could go wrong
This is an early Phase 1/2a trial with only 93 participants, so safety and effectiveness are not yet proven. The drug may cause side effects or not work as hoped.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Florida Cancer Specialists
Orlando, Florida, 32827, United States
-
MD Anderson Cancer Center
Houston, Texas, 77030, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065, United States
-
Oklahoma University
Oklahoma City, Oklahoma, 73104, United States
-
Sarah Cannon Research Institute
London, England, UK/W1G 6AD, United Kingdom
-
Tennessee Oncology
Nashville, Tennessee, 37203, United States
-
University of Pennsylvania/Abramson Cancer Center
Philadelphia, Pennsylvania, 19104, United States
-
Yale School of Medicine
New Haven, Connecticut, 06520, United States